2'-desoxy-2'-azidocytidine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2'-desoxy-2'-azidocytidine
• 英文别名: 2'-azido-2'-desoxycytidine；4-amino-1-[(2R,4S,5R)-3-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
• 化学式: C₉H₁₂N₆O₄
• 分子量: 268.232
• InChiKey: FEOYKPQEERVCAV-RNMRRNDGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  碳酸二苯酯 、 尿嘧啶核苷 在 碳酸氢钠 作用下， 以 甲醇 、 六甲基磷酰三胺 、 氯仿 、 水 、 乙酸乙酯 、 丙酮 为溶剂， 生成 2'-desoxy-2'-azidocytidine
  参考文献：
  名称：

  Methods for the treatment of viral infections

  摘要：

  提供了用于抑制细胞生长的组合物，特别是用于治疗病毒感染的组合物，包括核苷2'-氮杂-2'-脱氧胞苷。

  公开号：

  US04331662A1

文献信息

• [EN] COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA<br/>[FR] COMPOSITION ET MÉTHODES DE TRAITEMENT D'UNE DYSKINÉSIE CILIAIRE PRIMITIVE
  申请人：TRANSLATE BIO INC

  公开号：WO2021226463A1

  公开（公告）日：2021-11-11

  The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal intermediate chain 1 (DNAI1) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAI1 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.

  本发明提供了治疗原发性纤毛运动障碍（PCD）的方法和组合物，基于mRNA疗法。用于治疗PCD的组合物包括一个包含动力蛋白纤毛中间链1（DNAI1）编码序列的mRNA，以有效剂量和给药间隔进行给药，以使PCD的至少一个症状或特征在强度、严重程度、频率上减轻，或延迟发作。提供了具有优化DNAI1编码序列的mRNA，可以在不需要修改mRNA核苷酸的情况下进行给药，以实现体内持续功能。
• Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens
  申请人：Singleton Fain Scott

  公开号：US20060199768A1

  公开（公告）日：2006-09-07

  Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. Methods of screening for and methods of using the compounds are also provided.

  提供了用于调节RecA蛋白活性的化合物。在某些实施例中，这些化合物通过干扰单体RecA蛋白亚基的组装成为核蛋白丝来调节RecA活性。在某些实施例中，这些化合物通过干扰RecA蛋白的三磷酸腺苷水解来调节RecA活性。还提供了筛选这些化合物的方法和使用这些化合物的方法。
• Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs
  申请人：Drug Innovation & Design, Inc.

  公开号：US20030138432A1

  公开（公告）日：2003-07-24

  The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

  本发明涉及一种新的选择性细胞靶向的组合物、方法和应用。本发明的目的是为了实现对目标细胞的选择性输送和/或选择性激活效应分子，以进行诊断或治疗。本发明涉及多功能前药或靶向载体，其中每个功能都能增强靶向选择性、亲和力、细胞内转运、激活或解毒。本发明还涉及超低剂量、多靶点、多药物化疗和靶向免疫疗法，用于癌症治疗。
• ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
  申请人：Moderna Therapeutics, Inc.

  公开号：US20150167017A1

  公开（公告）日：2015-06-18

  The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.

  本公开提供了替代核苷、核苷酸和核酸以及它们的使用方法。
• Complexes of RNA and cationic peptides for transfection and for immunostimulation
  申请人：CureVac GmbH

  公开号：EP2484770A1

  公开（公告）日：2012-08-08

  The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x with the majority of the residues being selected from Arg, Lys, His, Orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.

  本发明涉及一种复合 RNA，包括至少一种与一种或多种寡肽复合的 RNA，其中寡肽的长度为 8 至 15 个氨基酸，具有经验式 (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x，大部分残基选自 Arg、Lys、His、Orn。本发明进一步涉及一种转染细胞或生物体的方法，从而应用本发明的复合 RNA。此外，本文还公开了包含本发明络合 RNA 的药物组合物和试剂盒，以及本发明络合 RNA 用于转染细胞、组织或生物体和/或调节、优选诱导或增强免疫反应的用途。